The company's regional brand competitive advantage is outstanding. As one of the old brands of traditional Chinese medicine with hundreds of years of history, the company is rich in variety resources, and its sales network is relatively sound. Its specialty products are well known in Hunan and other regions, but it is also facing problems that need to be solved urgently, such as the solidification of the management mechanism. By rationalizing sales resources and promoting strategic transformation, successfully achieving market expansion outside the province is a breakthrough point for the company's future development; marketing changes are underway, and subsequent progress is worth paying attention to. The company's pharmaceutical industry is mainly based on proprietary Chinese medicines. Sales revenue of concentrated pills such as donkey gum blood supplements and Liuwei Dihuang pills is over 200 million. In the future, driven by effective measures such as terminal concessions, the two major products are expected to achieve steady growth. Second-line products such as Siqikang injection, Nuhua Zi Bead tablets, Zu Guang San, kidney and tooth strengthening pills, and stomach and ulcer healing tablets have good growth potential. With channel adjustments in place, the future will usher in a period of relatively rapid growth. The pharmaceutical business is undergoing transformation and optimization, and the sales scale has remained stable in recent years. In the future, structural adjustments will continue to be made to increase the proportion of retail businesses with high gross profit; it will take time for health products to become large-scale. The company is currently planning to enter the fields of health products, food, etc., and will enrich the product line through self-production/exclusive agency/acquisition. Since it has certain brand advantages and retail pharmacy chain resources, it is expected that developing health food etc. will be one of the company's important future development trends by referring to the Tongrentang Health Pharmaceutical business model, but the results are yet to be seen; management is stabilizing. The company's executives have changed quite frequently in recent years. After the new general manager took office in January of this year, the management team has become more and more stable and united. It is expected that the majority shareholders will continue to give the company greater support and recommended ratings. Overall, the market where the company's leading products are fiercely competitive. This year will be a year where the marketing foundation is consolidated, and expenses will be invested a lot. In the future, we will closely follow the company's sales expansion progress. The company's EPS for 2012-14 is expected to be 0.71, 0.89, and 1.13 yuan, respectively, up 5%, 25%, and 26% year-on-year, respectively. Recommended investment ratings are given, and timely intervention is recommended.